BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 29733838)

  • 1. Validation of Prostate Imaging Reporting and Data System Version 2 for the Detection of Prostate Cancer.
    Hofbauer SL; Maxeiner A; Kittner B; Heckmann R; Reimann M; Wiemer L; Asbach P; Haas M; Penzkofer T; Stephan C; Friedersdorff F; Fuller F; Miller K; Cash H
    J Urol; 2018 Oct; 200(4):767-773. PubMed ID: 29733838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Evaluation of PI-RADS™ Version 2 Using the International Society of Urological Pathology Prostate Cancer Grade Group System.
    Mehralivand S; Bednarova S; Shih JH; Mertan FV; Gaur S; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
    J Urol; 2017 Sep; 198(3):583-590. PubMed ID: 28373133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is it Time to Perform Only Magnetic Resonance Imaging Targeted Cores? Our Experience with 1,032 Men Who Underwent Prostate Biopsy.
    Pepe P; Garufi A; Priolo GD; Galia A; Fraggetta F; Pennisi M
    J Urol; 2018 Oct; 200(4):774-778. PubMed ID: 29679618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection.
    Mertan FV; Greer MD; Shih JH; George AK; Kongnyuy M; Muthigi A; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
    J Urol; 2016 Sep; 196(3):690-6. PubMed ID: 27101772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
    J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30142318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
    J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30577397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/transrectal ultrasound fusion biopsy.
    Cash H; Maxeiner A; Stephan C; Fischer T; Durmus T; Holzmann J; Asbach P; Haas M; Hinz S; Neymeyer J; Miller K; Günzel K; Kempkensteffen C
    World J Urol; 2016 Apr; 34(4):525-32. PubMed ID: 26293117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anterior Localization of Prostate Cancer Suspicious Lesions in 1,161 Patients Undergoing Magnetic Resonance Imaging/Ultrasound Fusion Guided Targeted Biopsies.
    Leyh-Bannurah SR; Kachanov M; Beyersdorff D; Preisser F; Tilki D; Fisch M; Graefen M; Budäus L
    J Urol; 2018 Nov; 200(5):1035-1040. PubMed ID: 29935274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance.
    Radtke JP; Kuru TH; Boxler S; Alt CD; Popeneciu IV; Huettenbrink C; Klein T; Steinemann S; Bergstraesser C; Roethke M; Roth W; Schlemmer HP; Hohenfellner M; Hadaschik BA
    J Urol; 2015 Jan; 193(1):87-94. PubMed ID: 25079939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of Clinically Significant Prostate Cancer Associated With Prostate Imaging Reporting and Data System Category 3 (Equivocal) Lesions Identified on Multiparametric Prostate MRI.
    Sheridan AD; Nath SK; Syed JS; Aneja S; Sprenkle PC; Weinreb JC; Spektor M
    AJR Am J Roentgenol; 2018 Feb; 210(2):347-357. PubMed ID: 29112469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Institutional Learning Curve of Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy: Temporal Improvements in Cancer Detection in 4 Years.
    Meng X; Rosenkrantz AB; Huang R; Deng FM; Wysock JS; Bjurlin MA; Huang WC; Lepor H; Taneja SS
    J Urol; 2018 Nov; 200(5):1022-1029. PubMed ID: 29886090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy.
    Hansen NL; Kesch C; Barrett T; Koo B; Radtke JP; Bonekamp D; Schlemmer HP; Warren AY; Wieczorek K; Hohenfellner M; Kastner C; Hadaschik B
    BJU Int; 2017 Nov; 120(5):631-638. PubMed ID: 27862869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
    Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
    Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
    Lim CS; Abreu-Gomez J; Carrion I; Schieda N
    AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
    [No Abstract]   [Full Text] [Related]  

  • 15. Primary magnetic resonance imaging/ultrasonography fusion-guided biopsy of the prostate.
    Maxeiner A; Kittner B; Blobel C; Wiemer L; Hofbauer SL; Fischer T; Asbach P; Haas M; Penzkofer T; Fuller F; Miller K; Cash H
    BJU Int; 2018 Aug; 122(2):211-218. PubMed ID: 29569320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of histological findings obtained combining US/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative.
    Faiella E; Santucci D; Greco F; Frauenfelder G; Giacobbe V; Muto G; Zobel BB; Grasso RF
    Radiol Med; 2018 Feb; 123(2):143-152. PubMed ID: 29019021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy-naïve men with suspicion of prostate cancer.
    Hansen NL; Barrett T; Kesch C; Pepdjonovic L; Bonekamp D; O'Sullivan R; Distler F; Warren A; Samel C; Hadaschik B; Grummet J; Kastner C
    BJU Int; 2018 Jul; 122(1):40-49. PubMed ID: 29024425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining Novel and Practical Metrics to Assess the Deliverables of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy.
    Ristau BT; Chen DYT; Ellis J; Malhotra A; DeMora L; Parsons RB; Milestone B; Brody M; Viterbo R; Greenberg R; Smaldone M; Uzzo R; Anaokar J; Kutikov A
    J Urol; 2018 Apr; 199(4):969-975. PubMed ID: 28988963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of prostate cancer detection in MRI PI-RADS 3 lesions - Reality of a tertiary center.
    Araújo D; Gromicho A; Dias J; Bastos S; Maciel RM; Sabença A; Xambre L
    Arch Ital Urol Androl; 2023 Dec; 95(4):11830. PubMed ID: 38117217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk Stratification of Prostate Cancer According to PI-RADS® Version 2 Categories: Meta-Analysis for Prospective Studies.
    Park KJ; Choi SH; Lee JS; Kim JK; Kim MH; Jeong IG
    J Urol; 2020 Dec; 204(6):1141-1149. PubMed ID: 32716687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.